ALBPS — Biophytis SA Share News
0.000.00%
Last trade - 00:00Brief: Biophytis Announces Next Regulatory Steps In Europe and U.S. For Cova Project
Brief: Biophytis Receives Positive Opinion For Its Sara-31Phase 3 Study In Sarcopenia In Europe
French and Benelux stocks-Factors to watch
Brief: Biophytis Requests Pre-Submission Meeting With FDA For Emergency Use Authorization Of Sarconeos For Treatment Of Covid-19
Brief: Biophytis, Seqens Sign A Partnership To Produce Sarconeos Active Compound
French and Benelux stocks-Factors to watch
Brief: Biophytis Files With FDA For Authorization To Initiate Sara-31 Phase 3 Study In Sarcopenia
Brief: Biophytis Reports Clinical Results For Sarconeos (BIO101)
Brief: Biophytis Filed With HAS Application For Early Access Authorisation For Sarconeos
Brief: Biophytis Presents Positive Results Of Phase 2-3 Cova Study At American Thoracic Society International Conference
Brief: Biophytis Files With EMA For Authorization To Initiate SARA-31 Phase 3 Study In Sarcopenia
Brief: Biophytis Requests Pre-Submission Meeting With EMA To Discuss Marketing Authorisation For Treatment Of Covid-19
Brief: Biophytis Has Until June 8 To Submit Plan To Regain Compliance With Nasdaq Listing Rule
Brief: Biophytis Appoints Nicolas Fellmann As New CFO
Brief: Biophytis Announces Receipt Of Nasdaq Notice
Brief: Biophytis SA Files For Mixed Shelf Of Up To $100 Million
Brief: Biophytis says €11.1M Of Available Cash & Equivalents On Dec 31, 2022
Brief: Biophytis Announces Ratio Change Under Its American Depositary Receipt Program
Brief: Biophytis To Present Phase 2-3 Cova Study Results